PetMed Express (PETS) Expected to Announce Quarterly Earnings on Tuesday

PetMed Express (NASDAQ:PETS) is expected to be issuing its Q4 2025 quarterly earnings data after the market closes on Tuesday, June 10th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $54.00 million for the quarter.

PetMed Express Stock Up 3.2%

NASDAQ:PETS opened at $3.82 on Tuesday. PetMed Express has a 12-month low of $2.90 and a 12-month high of $6.85. The firm has a market capitalization of $78.91 million, a PE ratio of 382.38 and a beta of 0.76. The firm has a 50-day moving average price of $3.56 and a 200 day moving average price of $4.35.

Insider Buying and Selling at PetMed Express

In other news, major shareholder Silvercape Investments Ltd purchased 7,401 shares of PetMed Express stock in a transaction dated Tuesday, May 20th. The shares were bought at an average cost of $3.95 per share, with a total value of $29,233.95. Following the completion of the transaction, the insider now directly owns 2,307,719 shares in the company, valued at $9,115,490.05. This trade represents a 0.32% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sandra Yvette Campos sold 60,463 shares of PetMed Express stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $3.31, for a total transaction of $200,132.53. Following the transaction, the chief executive officer now directly owns 578,524 shares in the company, valued at approximately $1,914,914.44. This represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.

Hedge Funds Weigh In On PetMed Express

An institutional investor recently raised its position in PetMed Express stock. Goldman Sachs Group Inc. increased its stake in shares of PetMed Express, Inc. (NASDAQ:PETS) by 59.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,209 shares of the company’s stock after acquiring an additional 12,360 shares during the period. Goldman Sachs Group Inc. owned about 0.16% of PetMed Express worth $139,000 as of its most recent SEC filing. 73.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on PETS shares. Wall Street Zen lowered shares of PetMed Express from a “buy” rating to a “hold” rating in a report on Wednesday, May 7th. Morgan Stanley lowered their price target on shares of PetMed Express from $3.50 to $3.20 and set an “underweight” rating for the company in a report on Thursday, April 17th.

PetMed Express Company Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.